世界の神経腫瘍随伴症候群市場2020年:企業別・地域別・種類別・用途別市場予測(~2025年)

GlobalInfoResearchが発行した調査報告書(GIR20SP13378)
◆英語タイトル:Global Neurologic Paraneoplastic SyndromeTreatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025
◆商品コード:GIR20SP13378
◆発行会社(リサーチ会社):GlobalInfoResearch
◆発行日:2020年9月25日(※2024年版があります。お問い合わせください。)
◆ページ数:103
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療、製薬、バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalInfoResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、神経腫瘍随伴症候群の世界市場を広く調査・分析し、今後の市場展望をまとめております。神経腫瘍随伴症候群の種類別市場規模(薬、スピーチセラピー、その他)、用途別市場規模(病院、クリニック、外来手術センター、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。
・市場概要
・企業情報(販売量、市場シェア、製品概要、SWOT分析):Siemens Healthineers、Neusoft Medical Systems、Esaote、Koninklijke Philips、York Instruments、General Electric、Masimo、NeuroLogica、Canon Medical Systems
・地域別グローバル市場分析 2015年-2020年
・神経腫瘍随伴症候群の北米市場(アメリカ、カナダ、メキシコ)
・神経腫瘍随伴症候群のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・神経腫瘍随伴症候群のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・神経腫瘍随伴症候群の南米市場(ブラジル、アルゼンチン)
・神経腫瘍随伴症候群の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:薬、スピーチセラピー、その他
・用途別分析:病院、クリニック、外来手術センター、その他
・地域別市場規模予測 2021年-2025年
・調査の結果・結論
【レポートの概要】

Market Overview
The global Neurologic Paraneoplastic SyndromeTreatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Neurologic Paraneoplastic SyndromeTreatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Neurologic Paraneoplastic SyndromeTreatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Neurologic Paraneoplastic SyndromeTreatment market has been segmented into:
Medication
Speech Therapy
Others

By Application, Neurologic Paraneoplastic SyndromeTreatment has been segmented into:
Hospitals
Clinics
Ambulatory Surgical Centers
Others

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Neurologic Paraneoplastic SyndromeTreatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Neurologic Paraneoplastic SyndromeTreatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Neurologic Paraneoplastic SyndromeTreatment market.

The report offers in-depth assessment of the growth and other aspects of the Neurologic Paraneoplastic SyndromeTreatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Neurologic Paraneoplastic SyndromeTreatment Market Share Analysis
Neurologic Paraneoplastic SyndromeTreatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Neurologic Paraneoplastic SyndromeTreatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Neurologic Paraneoplastic SyndromeTreatment sales, revenue and market share for each player covered in this report.

The major players covered in Neurologic Paraneoplastic SyndromeTreatment are:
Siemens Healthineers
Neusoft Medical Systems
Esaote
Koninklijke Philips
York Instruments
General Electric
Masimo
NeuroLogica
Canon Medical Systems

【レポートの目次】

Table of Contents

1 Neurologic Paraneoplastic SyndromeTreatment Market Overview
1.1 Product Overview and Scope of Neurologic Paraneoplastic SyndromeTreatment
1.2 Classification of Neurologic Paraneoplastic SyndromeTreatment by Type
1.2.1 Global Neurologic Paraneoplastic SyndromeTreatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Neurologic Paraneoplastic SyndromeTreatment Revenue Market Share by Type in 2019
1.2.3 Medication
1.2.4 Speech Therapy
1.2.5 Others
1.3 Global Neurologic Paraneoplastic SyndromeTreatment Market by Application
1.3.1 Overview: Global Neurologic Paraneoplastic SyndromeTreatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Others
1.4 Global Neurologic Paraneoplastic SyndromeTreatment Market by Regions
1.4.1 Global Neurologic Paraneoplastic SyndromeTreatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Neurologic Paraneoplastic SyndromeTreatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Neurologic Paraneoplastic SyndromeTreatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Neurologic Paraneoplastic SyndromeTreatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Neurologic Paraneoplastic SyndromeTreatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Neurologic Paraneoplastic SyndromeTreatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Neurologic Paraneoplastic SyndromeTreatment Status and Prospect (2015-2025)
2 Company Profiles
2.1 Siemens Healthineers
2.1.1 Siemens Healthineers Details
2.1.2 Siemens Healthineers Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Siemens Healthineers SWOT Analysis
2.1.4 Siemens Healthineers Product and Services
2.1.5 Siemens Healthineers Neurologic Paraneoplastic SyndromeTreatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 Neusoft Medical Systems
2.2.1 Neusoft Medical Systems Details
2.2.2 Neusoft Medical Systems Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Neusoft Medical Systems SWOT Analysis
2.2.4 Neusoft Medical Systems Product and Services
2.2.5 Neusoft Medical Systems Neurologic Paraneoplastic SyndromeTreatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 Esaote
2.3.1 Esaote Details
2.3.2 Esaote Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Esaote SWOT Analysis
2.3.4 Esaote Product and Services
2.3.5 Esaote Neurologic Paraneoplastic SyndromeTreatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 Koninklijke Philips
2.4.1 Koninklijke Philips Details
2.4.2 Koninklijke Philips Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Koninklijke Philips SWOT Analysis
2.4.4 Koninklijke Philips Product and Services
2.4.5 Koninklijke Philips Neurologic Paraneoplastic SyndromeTreatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 York Instruments
2.5.1 York Instruments Details
2.5.2 York Instruments Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 York Instruments SWOT Analysis
2.5.4 York Instruments Product and Services
2.5.5 York Instruments Neurologic Paraneoplastic SyndromeTreatment Revenue, Gross Margin and Market Share (2018-2019)
2.6 General Electric
2.6.1 General Electric Details
2.6.2 General Electric Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 General Electric SWOT Analysis
2.6.4 General Electric Product and Services
2.6.5 General Electric Neurologic Paraneoplastic SyndromeTreatment Revenue, Gross Margin and Market Share (2018-2019)
2.7 Masimo
2.7.1 Masimo Details
2.7.2 Masimo Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Masimo SWOT Analysis
2.7.4 Masimo Product and Services
2.7.5 Masimo Neurologic Paraneoplastic SyndromeTreatment Revenue, Gross Margin and Market Share (2018-2019)
2.8 NeuroLogica
2.8.1 NeuroLogica Details
2.8.2 NeuroLogica Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 NeuroLogica SWOT Analysis
2.8.4 NeuroLogica Product and Services
2.8.5 NeuroLogica Neurologic Paraneoplastic SyndromeTreatment Revenue, Gross Margin and Market Share (2018-2019)
2.9 Canon Medical Systems
2.9.1 Canon Medical Systems Details
2.9.2 Canon Medical Systems Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Canon Medical Systems SWOT Analysis
2.9.4 Canon Medical Systems Product and Services
2.9.5 Canon Medical Systems Neurologic Paraneoplastic SyndromeTreatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Neurologic Paraneoplastic SyndromeTreatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Neurologic Paraneoplastic SyndromeTreatment Players Market Share
3.2.2 Top 10 Neurologic Paraneoplastic SyndromeTreatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Neurologic Paraneoplastic SyndromeTreatment Revenue and Market Share by Regions
4.2 North America Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
4.3 Europe Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
4.5 South America Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
5 North America Neurologic Paraneoplastic SyndromeTreatment Revenue by Countries
5.1 North America Neurologic Paraneoplastic SyndromeTreatment Revenue by Countries (2015-2020)
5.2 USA Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
5.3 Canada Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
6 Europe Neurologic Paraneoplastic SyndromeTreatment Revenue by Countries
6.1 Europe Neurologic Paraneoplastic SyndromeTreatment Revenue by Countries (2015-2020)
6.2 Germany Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
6.3 UK Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
6.4 France Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
6.5 Russia Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
6.6 Italy Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Neurologic Paraneoplastic SyndromeTreatment Revenue by Countries
7.1 Asia-Pacific Neurologic Paraneoplastic SyndromeTreatment Revenue by Countries (2015-2020)
7.2 China Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
7.3 Japan Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
7.4 Korea Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
7.5 India Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
8 South America Neurologic Paraneoplastic SyndromeTreatment Revenue by Countries
8.1 South America Neurologic Paraneoplastic SyndromeTreatment Revenue by Countries (2015-2020)
8.2 Brazil Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Neurologic Paraneoplastic SyndromeTreatment by Countries
9.1 Middle East & Africa Neurologic Paraneoplastic SyndromeTreatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
9.3 UAE Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Neurologic Paraneoplastic SyndromeTreatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Neurologic Paraneoplastic SyndromeTreatment Revenue and Market Share by Type (2015-2020)
10.2 Global Neurologic Paraneoplastic SyndromeTreatment Market Forecast by Type (2019-2024)
10.3 Medication Revenue Growth Rate (2015-2025)
10.4 Speech Therapy Revenue Growth Rate (2015-2025)
10.5 Others Revenue Growth Rate (2015-2025)
11 Global Neurologic Paraneoplastic SyndromeTreatment Market Segment by Application
11.1 Global Neurologic Paraneoplastic SyndromeTreatment Revenue Market Share by Application (2015-2020)
11.2 Neurologic Paraneoplastic SyndromeTreatment Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Ambulatory Surgical Centers Revenue Growth (2015-2020)
11.6 Others Revenue Growth (2015-2020)
12 Global Neurologic Paraneoplastic SyndromeTreatment Market Size Forecast (2021-2025)
12.1 Global Neurologic Paraneoplastic SyndromeTreatment Market Size Forecast (2021-2025)
12.2 Global Neurologic Paraneoplastic SyndromeTreatment Market Forecast by Regions (2021-2025)
12.3 North America Neurologic Paraneoplastic SyndromeTreatment Revenue Market Forecast (2021-2025)
12.4 Europe Neurologic Paraneoplastic SyndromeTreatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Neurologic Paraneoplastic SyndromeTreatment Revenue Market Forecast (2021-2025)
12.6 South America Neurologic Paraneoplastic SyndromeTreatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Neurologic Paraneoplastic SyndromeTreatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

...

【掲載企業】

Siemens Healthineers、Neusoft Medical Systems、Esaote、Koninklijke Philips、York Instruments、General Electric、Masimo、NeuroLogica、Canon Medical Systems

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の神経腫瘍随伴症候群市場2020年:企業別・地域別・種類別・用途別市場予測(~2025年)(Global Neurologic Paraneoplastic SyndromeTreatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025)]についてメールでお問い合わせはこちらでお願いします。